| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yan-Yu Wang, Xu Yang, Yun-Chao Wang, Jun-Yu Long, Hui-Shan Sun, Yi-Ran Li, Zi-Yu Xun, Nan Zhang, Jing-Nan Xue, Cong Ning, Jun-Wei Zhang, Cheng-Pei Zhu, Long-Hao Zhang, Xiao-Bo Yang and Hai-Tao Zhao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences |
2021-I2M-1-061, 2021-I2M-1-003 |
| Chinese Society of Clinical Oncology-Hengrui Cancer Research Fund |
Y-HR2019-0239 |
| Chinese Society of Clinical Oncology-MSD Cancer Research Fund |
Y-MSDZD2021-0213 |
| National Ten-thousand Talent Program |
|
|
| Corresponding Author |
Hai-Tao Zhao, MD, PhD, Professor, Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1, Shuaifuyuan, Dongcheng District, Beijing 100730, China. zhaoht@pumch.cn |
| Key Words |
Lenvatinib; Programmed death receptor-1 inhibitor; Immunotherapy; Hepatocellular carcinoma; Transarterial chemoembolization; Combination therapy |
| Core Tip |
This retrospective research was designed to evaluate the treatment outcome and safety of transarterial chemoembolization (TACE) and lenvatinib plus programmed death receptor-1 (PD-1) inhibitors in the treatment of patients with unresectable hepatocellular carcinoma (uHCC). Patients with uHCC who underwent PD-1 inhibitors, lenvatinib, TACE therapy (n = 45) had a evidently longer overall survival than those who underrwent lenvatinib, TACE therapy (n = 20, 26.8 vs 14.0 mo; P = 0.027). Early combination of PD-1 inhibitors has manageable toxicity and hopeful efficacy in patients with uHCC. |
| Publish Date |
2023-03-10 07:29 |
| Citation |
Wang YY, Yang X, Wang YC, Long JY, Sun HS, Li YR, Xun ZY, Zhang N, Xue JN, Ning C, Zhang JW, Zhu CP, Zhang LH, Yang XB, Zhao HT. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma. World J Gastroenterol 2023; 29(10): 1614-1626 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i10/1614.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i10.1614 |
